Dr Clive Ballard just now! | ACAD Message Board Posts

ACADIA Pharmaceuticals Inc.

  ACAD website

ACAD   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  15696 of 16756  at  9/19/2019 7:05:49 PM  by


 In response to msg 15692 by  Nazaretti
view thread

Re: Dr Clive Ballard just now!

From JP Morgan analyst Cory Kasimov in a note to clients after the DRP news was released:
"The subtypes of DRP matched the overall epidemiology of the disease: 67% ADP, 15% PDP [I think Casimov meant to say PDD], 10% vascular dementia, <10% dementia with lewy bodies, <5% frontotemporal dementia."
Only 20% of those in the 12-week, open-label part of the study failed to proceed to the 26-week randomization period.
The question the FDA will ponder is whether to approve Nuplazid for all the DRP subtypes or confine approval to ADP. If the latter, sales will still explode, easily making Nuplazid a blockbuster drug.
In an annual report years ago, ACAD said that "more than five million people in the United States have Alzheimer's disease and, of these patients, an estimated 25% to 50% suffer from ADP." If that figure is still accurate -- ACAD has since revised those numbers to include the whole DRP class -- it comes out to between 1.2 and 2.5 million patients just in the U.S.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 445
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
15697 Re: Dr Clive Ballard just now! longusa 6 9/19/2019 7:53:38 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by